A New Gene Therapy Series Starts Today with Regenxbio

Beyond the firms that are speeding towards bringing prophylactic vaccines against the COVID-19 infection into the clinic we have to consider the other firms that have been negatively affected by the virus pandemic; we expect them to rebound and surge when the virus loses its ability to kill.

We decided to start with gene therapy companies that we believe have suffered from the delays of their clinical trials as the hospitals are being filled with COVID-19 patients.           

The gene therapy firm Regenxbio (

Please click here to subscribe or here to log in.